157 related articles for article (PubMed ID: 38660881)
1. [Pathogenesis and Therapeutic Prospects of Chronic Graft-Versus-Host Disease --Review].
Xu SH; Man Y; Zhao JL; Wang YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):647-652. PubMed ID: 38660881
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Toubai T; Hosokawa Y
Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
[TBL] [Abstract][Full Text] [Related]
3. Immune Ablation and Stem Cell Rescue in Two Pediatric Patients with Progressive Severe Chronic Graft-Versus-Host Disease.
Kloehn J; Kruchen A; Schütze K; Wustrau K; Schrum J; Müller I
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499733
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and research progress in biomarkers for chronic graft versus host disease.
Ji R; Li Y; Huang R; Xiong J; Wang X; Zhang X
Crit Rev Oncol Hematol; 2023 Jun; 186():103993. PubMed ID: 37061073
[TBL] [Abstract][Full Text] [Related]
5. [Latest research progress on pathogenesis of chronic graft versus host disease and its related problems].
Li XM; Zhu H; Zhou F; Zhang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):549-54. PubMed ID: 24763041
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
7. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
10. Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E; Loren AW; Falk SJ; Mays JW; Cowen EW
J Am Acad Dermatol; 2024 Jan; 90(1):19-36. PubMed ID: 36572064
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].
Cheng XJ; Ji R; Huan RH; Huang SQ; Fan W; Zhao YC; Yuan RD; Wang XQ; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):242-248. PubMed ID: 38716595
[No Abstract] [Full Text] [Related]
12. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
13. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
14. [Chronic graft-versus-host disease].
Rørvik SD; Abrahamsen IW; Myhre AE; Vo CD; Ødegaard EM; Bruserud Ø; Gedde-Dahl T; Tvedt THA
Tidsskr Nor Laegeforen; 2023 Mar; 143(4):. PubMed ID: 36919292
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
16. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
18. Developing role of B cells in the pathogenesis and treatment of chronic GVHD.
Li X; Gao Q; Feng Y; Zhang X
Br J Haematol; 2019 Feb; 184(3):323-336. PubMed ID: 30585319
[TBL] [Abstract][Full Text] [Related]
19. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
Michonneau D; Quignot N; Jiang H; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):514-525. PubMed ID: 36765178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
